We invite postgraduate research proposals in a number of disease areas that impact significantly on patient care. We focus on exploring the mechanisms of disease, understanding the ways disease impacts patients’ lives, utilising new diagnostic and therapeutic techniques and developing new treatments.
As a student you will be registered with a University research institute, for many this is the Institute for Cellular Medicine (ICM). You will be supported in your studies through a structured programme of supervision and training via our Faculty of Medical Sciences Graduate School.
We undertake the following areas of research and offer MPhil, PhD and MD supervision in:
Newcastle hosts one of the most comprehensive organ transplant programmes in the world. This clinical expertise has developed in parallel with the applied immunobiology and transplantation research group. We are investigating aspects of the immunology of autoimmune diseases and cancer therapy, in addition to transplant rejection. We have themes to understand the interplay of the inflammatory and anti-inflammatory responses by a variety of pathways, and how these can be manipulated for therapeutic purposes. Further research theme focusses on primary immunodeficiency diseases.
There is strong emphasis on the integration of clinical investigation with basic science. Our research include:
We also research the effects of UVR on the skin including mitochondrial DNA damage as a UV biomarker.
This area emphasises on translational research, linking clinical- and laboratory-based science. Key research include:
Focus is on applied research and aims to underpin future clinical applications. Technology-oriented and demand-driven research is conducted which relates directly to health priority areas such as:
This research is sustained through extensive internal and external collaborations with leading UK and European academic and industrial groups, and has the ultimate goal of deploying next-generation diagnostic and therapeutic systems in the hospital and health-care environment.
There is a number of research programmes into the genetics, immunology and physiology of kidney disease and kidney transplantation. We maintain close links between basic scientists and clinicians with many translational programmes of work, from the laboratory to first-in-man and phase III clinical trials. Specific areas:
We have particular interests in:
Novel non-invasive methodologies using magnetic resonance are developed and applied to clinical research. Our research falls into two categories:
Our studies cover a broad range of topics (including diabetes, dementia, neuroscience, hepatology, cardiovascular, neuromuscular disease, metabolism, and respiratory research projects), but have a common theme of MR technical development and its application to clinical research.
We focus on connective tissue diseases in three, overlapping research programmes. These programmes aim to understand:
This research theme links with other local, national and international centres of excellence and has close integration of basic and clinical researchers and hosts the only immunotherapy centre in the UK.
Genetic approaches to the individualisation of drug therapy, including anticoagulants and anti-cancer drugs, and in the genetics of diverse non-Mendelian diseases, from diabetes to periodontal disease, are a focus. A wide range of knowledge and experience in both genetics and clinical sciences is utilised, with access to high-throughput genotyping platforms.
Our scientists and clinicians use in situ cellular technologies and large-scale gene expression profiling to study the normal and pathophysiological remodelling of vascular and uteroplacental tissues. Novel approaches to cellular interactions have been developed using a unique human tissue resource. Our research themes include:
We also have preclinical molecular biology projects in breast cancer research.
We conduct a broad range of research activities into acute and chronic lung diseases. As well as scientific studies into disease mechanisms, there is particular interest in translational medicine approaches to lung disease, studying human lung tissue and cells to explore potential for new treatments. Our current areas of research include:
Our research projects are concerned with the harmful effects of chemicals, including prescribed drugs, and finding ways to prevent and minimise these effects. We are attempting to measure the effects of fairly small amounts of chemicals, to provide ways of giving early warning of the start of harmful effects. We also study the adverse side-effects of medicines, including how conditions such as liver disease and heart disease can develop in people taking medicines for completely different medical conditions. Our current interests include: environmental chemicals and organophosphate pesticides, warfarin, psychiatric drugs and anti-cancer drugs.
Our new School of Pharmacy has scientists and clinicians working together on all aspects of pharmaceutical sciences and clinical pharmacy.
The only Master’s specialisation in the Netherlands covering the function of our epigenome, a key factor in regulating gene expression and in a wide range of diseases.
Our skin cells, liver cells and blood cells all contain the same genetic information. Yet these are different types of cells, each performing their own specific tasks. How is this possible? The explanation lies in the epigenome: a heritable, cell-type specific set of chromosomal modifications, which regulates gene expression. Radboud University is specialised in studying the epigenome and is the only university in the Netherlands to offer a Master’s programme in this field of research.
The epigenome consists of small and reversible chemical modifications of the DNA or histone proteins, such as methylation, acetylation and phosphorylation. It changes the spatial structure of DNA, resulting in gene activation or repression. These processes are crucial for our health and also play a role in many diseases, like autoimmune diseases, cancer and neurological disorders. As opposed to modifications of the genome sequence itself, epigenetic modifications are reversible. You can therefore imagine the great potential of drugs that target epigenetic enzymes, so-called epi-drugs.
In this specialisation, you’ll look at a cell as one big and complex system. You’ll study epigenetic mechanisms during development and disease from different angles. This includes studying DNA and RNA by next-generation sequencing (epigenomics) and analysing proteins by mass spectrometry (proteomics). In addition, you‘ll be trained to design computational strategies that allow the integration of these multifaceted, high-throughput data sets into one system.
- Radboud University combines various state-of-the-art technologies – such as quantitative mass spectrometry and next-generation DNA sequencing – with downstream bioinformatics analyses in one department. This is unique in Europe.
- This programme allows you to work with researchers from the Radboud Institute for Molecular Life sciences (RIMLS), one of the leading multidisciplinary research institutes within this field of study worldwide.
- We have close contacts with high-profile medically oriented groups on the Radboud campus and with international institutes (EMBL, Max-Planck, Marie Curie, Cambridge, US-based labs, etc). As a Master’s student, you can choose to perform an internship in one of these related departments.
- Radboud University coordinates BLUEPRINT, a 30 million Euro European project focusing on the epigenomics of leukaemia. Master’s students have the opportunity to participate in this project.
As a Master’s student of Medical Epigenomics you’re trained in using state-of-the art technology in combination with biological software tools to study complete networks in cells in an unbiased manner. For example, you’ll know how to study the effects of drugs in the human body.
When you enter the job market, you’ll have:
- A thorough background of epigenetic mechanisms in health and disease, which is highly relevant in strongly rising field of epi-drug development
- Extensive and partly hands-on experience in state-of-the-art ‘omics’ technologies: next-generation sequencing, quantitative mass spectrometry and single cell technologies;
- Extensive expertise in designing, executing and interpreting scientific experiments in data-driven research;
- The computational skills needed to analyse large ‘omics’ datasets.
With this background, you can become a researcher at a:
- University or research institute;
- Pharmaceutical company, such as Synthon or Johnson & Johnson;
- Food company, like Danone or Unilever;
- Start-up company making use of -omics technology.
Apart from research into genomics and epigenomics, you could also work on topics such as miniaturising workflows, improving experimental devices, the interface between biology and informatics, medicine from a systems approach.
Or you can become a:
- Biological or medical consultant;
- Biology teacher;
- Policy coordinator, regarding genetic or medical issues;
- Patent attorney;
- Clinical research associate;
Each year, the Molecular Biology department (Prof. Henk Stunnenberg, Prof. Michiel Vermeulen) and the Molecular Developmental Biology department (Prof. Gert-Jan Veenstra) at the RIMLS offer between five and ten PhD positions. Of course, many graduates also apply for a PhD position at related departments in the Netherlands, or abroad.
- Systems biology
In the Medical Epigenomics specialisation you won’t zoom in on only one particular gene, protein or signalling pathway. Instead, you’ll regard the cell as one complete system. This comprehensive view allows you to, for example, model the impact of one particular epigenetic mutation on various parts and functions of the cell, or study the effects of a drug in an unbiased manner. One of the challenges of this systems biology approach is the processing and integration of large amounts of data. That’s why you’ll also be trained in computational biology. Once graduated, this will be a great advantage: you’ll be able to bridge the gap between biology, technology and informatics , and thus have a profile that is desperately needed in modern, data-driven biology.
- Multiple OMICS approaches
Studying cells in a systems biology approach means connecting processes at the level of the genome (genomics), epigenome (epigenomics), transcriptome (transcriptomics), proteome (proteomics), etc. In the Medical Epigenomics specialisation, you’ll get acquainted with all these different fields of study.
- Patient and animal samples
Numerous genetic diseases are not caused by genetic mutations, but by epigenetic mutations that influence the structure and function of chromatin. Think of:
- Autoimmune diseases, like rheumatoid arthritis and lupus
- Cancer, in the forms of leukaemia, colon cancer, prostate cancer and cervical cancer
- Neurological disorders, like Rett Syndrome, Alzheimer, Parkinson, Multiple Sclerosis, schizophrenia and autism
We investigate these diseases on a cellular level, focusing on the epigenetic mutations and the impact on various pathways in the cell. You’ll get the chance to participate in that research, and work with embryonic stem cell, patient, Xenopus or zebra fish samples.
See the website http://www.ru.nl/masters/medicalbiology/epigenomics
The Centre for Inflammation Research (CIR) aims to promote the prevention, diagnosis and treatment of inflammatory diseases through interdisciplinary study of the initiation, regulation and resolution of inflammatory responses and provision of an outstanding environment for research training in the field.
CIR investigators aim to characterise and manipulate key control points in inflammation. We focus on:
We have particular interest in inflammatory diseases of the lung and kidney but the principles derived will have ready application to inflammatory responses in the liver, bowel, bone/joint and skin. There is also increasing development of research in the CIR into the links between inflammation and cancer.
The Centre was formally established in 1998.
Generic training in presentation skills, project management and writing skills is delivered through the University of Edinburgh's transferable skills programme.
The CIR is a multidisciplinary team of research groups under the directorship of Professor John Iredale. The CIR consists of more than 180 researchers, is equipped with state-of-the-art apparatus and is supported by external grant funding. The CIR is now located in the purpose-built Queen's Medical Research Institute along with the centres for Reproductive Biology and Cardiovascular Sciences.